Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.33 |
| ▸ | TUBB | P07437 | 3/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.33 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.33 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.33 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.33 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21376048 | 0.81 | TUBB4A (0.36) | TP53POLBTUBB4ATUBBTUBA3C | |
| SCHEMBL20150120 | 0.80 | TSHR (0.39) | TP53POLBMAPTSMN1; SMN2NPC1 | |
| SCHEMBL20150109 | 0.77 | TSHR (0.38) | TP53POLBTSHRALDH1A1ALOX15 | |
| SCHEMBL20230857 | 0.77 | TUBB4A (0.36) | TP53POLBTUBB4ATUBBTUBA3C | |
| SCHEMBL21784454 | 0.75 | TYK2 (0.37) | TSHRALOX15USP1WDR48CYP2C19 | |
| SCHEMBL20150087 | 0.75 | TP53 (0.37) | TP53POLBMAPTSMN1; SMN2RAB9A | |
| SCHEMBL20150114 | 0.75 | NPC1 (0.40) | TP53POLBMAPTSMN1; SMN2NPC1 | |
| SCHEMBL20150105 | 0.74 | TP53 (0.39) | TP53POLBMAPTTSHRALOX15 | |
| SCHEMBL20150097 | 0.73 | SCN9A (0.36) | TP53POLBMAPTNPC1RAB9A | |
| SCHEMBL20150095 | 0.73 | TSHR (0.33) | TP53POLBTSHRALOX15USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-10 | — | — | US | disclosed |
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10323036-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TP53 2843/4885POLB 1657/4885TUBB4A 2425/4885 |
| US-10323036-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TP53 2843/4885POLB 1657/4885TUBB4A 2425/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TP53 2843/4885POLB 1657/4885TUBB4A 2425/4885 |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TP53 2843/4885POLB 1657/4885TUBB4A 2425/4885 |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TP53 2843/4885POLB 1657/4885TUBB4A 2425/4885 |
| US-20220073527-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TP53 2843/4885POLB 1657/4885TUBB4A 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.